![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
We investigated the expression of the lymphocyte function associated (LFA)-1 adhesion molecule, recognized by the CD1 la and CD 18 monoclonal antibodies, in 53 patients with B-cell chronic lymphocytic leukemia (B-CLL) and in 37 controls. The mean percentage of control lymphocytes expressing CD1 la and CD 18 positivity was 92 ± 5.5 and 90 ± 8.7, respectively and, in patients with B-CLL, 14.2 ± 10.3 and 14.8 ± 10.3 respectively (p < 0.001). No statistical difference was found between CDlla and CD 18 expression and the Rai clinical stages. In our experience a decrease of LFA-1 is a constant finding in B-CLL, in the early stages of the disease. It may, therefore, be useful to differentiate between slight increases of neoplastic cells and reactive blood lymphocytosis.